课题基金 / 基金详情

Regulation of the paracrine angiogenic function of cardiac myocytes by cardiomyoc

Regulation of the paracrine angiogenic function of cardiac myocytes by cardiomyoc
心肌细胞旁分泌血管生成功能的调节
批准号:
8271279
负责人:
WADIH ARAP
金额:
$39.11万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-07-01 至 2015-05-31

项目摘要

项目成果

WADIH ARAP的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):新的观察结果表明,心肌细胞生长和心脏血管生成的过程必须在整个生命过程中保持平衡,并表明对应激反应的过度心脏肥大和/或心脏血管生成不足导致心脏功能受损、心肌病和心力衰竭。心脏生长和心脏血管生成之间的不平衡可能在多种形式的人类心力衰竭的发展和进展中起重要作用。有趣的是,最近的几项研究表明,心肌细胞本身以旁分泌的方式调节心脏血管的生长以应对压力。然而,这种旁分泌功能的心肌细胞(心肌细胞的血管生成潜力)的分子调控还没有得到很好的理解。我们的中心假设是,在导致心脏肥大的应激条件下,血小板衍生生长因子受体β(PDGFR-)是心肌细胞血管生成潜力的上游调节因子。为了支持这一假设,我们已经表明,心肌细胞特异性Pdgfrb基因敲除小鼠暴露于压力超负荷应激发展心功能不全,心室扩张和心力衰竭,与冠状动脉微血管功能缺陷。这些发现表明PDGFR信号是心脏应激反应的重要且迄今未被认识的介质。 为了进一步理解PDGFR-信号传导作为心肌细胞血管生成潜能的调节剂的作用,我们将使用Pdgfrb敲除模型以及还通过施用靶点包括PDGFR-的抗癌剂来确定心肌细胞PDGFR-信号传导是否响应于导致心脏肥大的病理性应激物调节冠状动脉血管生成(Aim One)。我们将使用Pdgfrb敲除模型进一步确定是否需要心肌细胞PDFGR信号传导来促进冠状动脉血管生成,所述冠状动脉血管生成伴随在出生后早期或成年生活中观察到的响应于运动训练的生理性心脏生长(目的二)。最后,我们将使用PDGFR-缺失的培养心肌细胞的体外模型来确定PDGFR-信号传导调节心肌细胞血管生成潜能的机制。通过本申请中提出的实验证实我们的总体假设将表明,心脏中的PDGFR可能是评估和治疗所选形式的人类心力衰竭的新的关注领域,并且此外,可以告知预防和/或治疗用靶向PDGFR信号传导的药剂治疗的癌症患者的心脏毒性的策略。 公共卫生相关性:本申请中提出的研究将寻求理解血小板衍生生长因子β(PDGFR-)(一种在包括心肌细胞在内的多种细胞类型的细胞表面上表达的蛋白质)在心肌生长期间调节心脏中的血管生长中的作用,心肌生长是由于各种应激源而发生的,其中一些应激源与心力衰竭的发展直接相关。从这项研究中获得的见解可用于开发治疗多种病因引起的人类心力衰竭的新治疗策略,也可用于帮助开发预防靶向PDGFR信号传导的抗癌药物引起的临床心脏毒性的策略。
英文摘要
DESCRIPTION (provided by applicant): Emerging observations indicate that the processes of cardiomyocyte growth and cardiac angiogenesis must remain balanced throughout life and suggest that excess cardiac hypertrophy and/or insufficient cardiac angiogenesis in response to stress leads to impaired cardiac function, cardiomyopathy, and heart failure. An imbalance between cardiac growth and cardiac angiogenesis may play an essential role in the development and progression of multiple forms of human heart failure. Intriguingly, several recent studies indicate that the cardiomyocyte itself functions in a paracrine fashion to regulate blood vessel growth in the heart in response to stress. However, the molecular regulation of this paracrine function of cardiomyocytes (the angiogenic potential of cardiomyocytes) is not well understood. Our central hypothesis is that under conditions of stress that lead to cardiac hypertrophy, platelet derived growth factor receptor beta (PDGFR-) is an upstream regulator of the angiogenic potential of cardiomyocytes. In support of this hypothesis, we have shown that cardiomyocyte specific Pdgfrb knockout mice exposed to pressure overload stress develop cardiac dysfunction, ventricular dilatation and heart failure, associated with defective coronary microvascular function. These findings demonstrate that PDGFR- signaling is an essential and heretofore unappreciated mediator of the cardiac stress response. To further understand the role of PDGFR- signaling as a regulator of the angiogenic potential of cardiomyocytes, we will determine if cardiomyocyte PDGFR- signaling regulates coronary angiogenesis in response to pathologic stressors that lead to cardiac hypertrophy using a Pdgfrb knockout model and also via administration of anti-cancer agents whose targets include PDGFR- (Aim One). We will further determine if cardiomyocyte PDFGR- signaling is required to promote coronary angiogenesis which accompanies physiologic cardiac growth observed in early postnatal life or in adult life in response to exercise training using a Pdgfrb knockout model (Aim Two). Finally, we will determine the mechanism(s) by which PDGFR- signaling regulates the angiogenic potential of cardiomyocytes using an in vitro model of cultured cardiomyocytes in which PDGFR- is deleted. Confirmation of our overall hypothesis through the experiments proposed in this application would suggest that PDGFR- in the heart may be a novel area of concern in evaluating and treating selected forms of human heart failure, and in addition, may inform strategies to prevent and/or treat cardiotoxicity in cancer patients treated with agents that target PDGFR signaling. PUBLIC HEALTH RELEVANCE: Studies proposed in this application will seek to understand the role of platelet derived growth factor beta (PDGFR-), a protein expressed on the cell surface of a number of cell types including heart muscle cells, in the regulation of blood vessel growth in the heart during heart muscle growth which occurs as a result of a variety of stressors, some of which are directly linked to the development of heart failure. Insights gained from this study may be used to develop novel therapeutic strategies for the treatment of human heart failure due to multiple etiologies, and may also be useful to help develop strategies to prevent clinical cardiac toxicity due to anti-cancer agents that target PDGFR signaling.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Designing a transcriptome-based, targeted theranostic platform for prostate cancer
Designing a transcriptome-based, targeted theranostic platform for prostate cancer
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer
海外基金